{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:56:02Z","timestamp":1789448162516,"version":"build-2803163510"},"reference-count":128,"publisher":"Harborside Press, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>Immune checkpoint inhibitors have transformed the therapeutic landscape of classic Hodgkin lymphoma (cHL), leading to significant improvement in patient outcomes in the modern era. This review provides an overview of the established and evolving roles of PD-1 inhibitors in the management of cHL. We highlight the pivotal trials of nivolumab and pembrolizumab in relapsed\/refractory cHL and discuss subsequent studies combining these agents with chemotherapy in the second-line setting, which have led to improved cure rates following autologous stem cell transplant (ASCT). In the frontline setting, the SWOG S1826 trial established nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (AVD) as the new standard of care for advanced-stage cHL in North America, improving progression-free survival and tolerability compared with brentuximab vedotin with AVD. In early-stage cHL, PD-1 inhibitors are being explored as part of treatment strategies to omit bleomycin and\/or radiotherapy. PD-1 inhibitor\u2013based regimens have also become a new standard for older adults with cHL, leading to improved overall survival in this population with historically poorer outcomes compared with younger patients. We address the challenging scenario of managing patients with disease relapse after PD-1 inhibitor therapy, including novel combination strategies aimed at restoring sensitivity to checkpoint blockade. Finally, we highlight emerging directions in the field, including efforts to develop predictive biomarkers and to incorporate circulating tumor DNA\u2013based strategies to monitor response and personalize therapy, with the potential to abbreviate chemotherapy or omit ASCT in a subset of patients. As PD-1 inhibitors are increasingly incorporated across treatment regimens for cHL, ongoing studies aim to refine patient selection, identify those most likely to benefit from therapy escalation or de-escalation, and optimize therapeutic combinations to maximize cure rates, tolerability, and survivorship.<\/jats:p>","DOI":"10.6004\/jnccn.2025.7125","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:46:29Z","timestamp":1770644789000},"source":"Crossref","is-referenced-by-count":2,"title":["Optimizing the Role of Checkpoint Inhibitors in the Management of Hodgkin Lymphoma"],"prefix":"10.6004","volume":"24","author":[{"given":"Sirui","family":"Ma","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California, Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Spinner","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California, Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"N Engl J Med","first-page":"1379","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera AF","year":"2024","unstructured":"Herrera AF, LeBlanc M, Castellino SM,  Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma. N Engl J Med 2024;391:1379\u20131389."},{"key":"B2","series-title":"Blood","first-page":"2727","article-title":"Improved outcomes for relapsed\/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents","volume":"141","author":"Spinner MA","year":"2023","unstructured":"Spinner MA, Sica RA, Tamaresis JS,  Improved outcomes for relapsed\/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood 2023;141:2727\u20132737."},{"key":"B3","series-title":"N Engl J Med","first-page":"311","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell SM","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I,  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 2015;372:311\u2013319."},{"key":"B4","series-title":"J Clin Oncol","first-page":"2125","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen R","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA,  Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35:2125\u20132132."},{"key":"B5","series-title":"J Clin Oncol","first-page":"2690","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer MGM","year":"2016","unstructured":"Roemer MGM, Advani RH, Ligon AH,  PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 2016;34:2690\u20132697."},{"key":"B6","series-title":"Blood","first-page":"2420","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey CD","year":"2017","unstructured":"Carey CD, Gusenleitner D, Lipschitz M,  Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood 2017;130:2420\u20132430."},{"key":"B7","series-title":"Lancet Oncol","first-page":"1283","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes A","year":"2016","unstructured":"Younes A, Santoro A, Shipp M,  Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17:1283\u20131294."},{"key":"B8","series-title":"Blood Adv","first-page":"6266","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study","volume":"7","author":"Ansell SM","year":"2023","unstructured":"Ansell SM, Br\u00f6ckelmann PJ, von Keudell G,  Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv 2023;7:6266\u20136274."},{"key":"B9","series-title":"Blood","first-page":"878","article-title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"Armand P","year":"2023","unstructured":"Armand P, Zinzani PL, Lee HJ,  Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma. Blood 2023;142:878\u2013886."},{"key":"B10","series-title":"Lancet Oncol","first-page":"512","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla J","year":"2021","unstructured":"Kuruvilla J, Ramchandren R, Santoro A,  Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021;22:512\u2013524."},{"key":"B11","series-title":"Blood Adv","first-page":"590","article-title":"Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed\/refractory classical Hodgkin lymphoma","volume":"6","author":"Zinzani PL","year":"2022","unstructured":"Zinzani PL, Ramchandren R, Santoro A,  Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed\/refractory classical Hodgkin lymphoma. Blood Adv 2022;6:590\u2013599."},{"key":"B12","article-title":"NCCN Guidelines\u00ae Insights: Hodgkin Lymphoma, Version 1.2026","author":"Advani RH","unstructured":"Advani RH, Kelsey CR, Armand P,  NCCN Guidelines\u00ae Insights: Hodgkin Lymphoma, Version 1.2026. Accessed December 16, 2025. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf"},{"key":"B13","series-title":"Blood","first-page":"4934","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz AJ","year":"2010","unstructured":"Moskowitz AJ, Yahalom J, Kewalramani T,  Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010;116:4934\u20134937."},{"key":"B14","series-title":"Cancers (Basel)","first-page":"4509.","article-title":"Optimizing treatment for relapsed\/refractory classic Hodgkin lymphoma in the era of immunotherapy","volume":"15","author":"Randall MP","year":"2023","unstructured":"Randall MP, Spinner MA. Optimizing treatment for relapsed\/refractory classic Hodgkin lymphoma in the era of immunotherapy. Cancers (Basel) 2023;15:4509."},{"key":"B15","series-title":"Blood","first-page":"427","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani RH","year":"2021","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL,  Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood 2021;138:427\u2013438."},{"key":"B16","series-title":"Blood","first-page":"3605","article-title":"Response-adapted anti-PD-1\u2013based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei MG","year":"2022","unstructured":"Mei MG, Lee HJ, Palmer JM,  Response-adapted anti-PD-1\u2013based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood 2022;139:3605\u20133616."},{"key":"B17","series-title":"JAMA Oncol","first-page":"683","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma","volume":"9","author":"Bryan LJ","year":"2023","unstructured":"Bryan LJ, Casulo C, Allen PB,  Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma. JAMA Oncol 2023;9:683\u2013691."},{"key":"B18","series-title":"J Clin Oncol","first-page":"3109","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz AJ","year":"2021","unstructured":"Moskowitz AJ, Shah G, Sch\u00f6der H,  Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol 2021;39:3109\u20133117."},{"key":"B19","series-title":"Hemasphere","first-page":"45","article-title":"T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma","volume":"6","author":"Moskowitz AJ","year":"2022","unstructured":"Moskowitz AJ, Shah G, Sch\u00f6der H,  T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma. Hemasphere 2022;6:45\u201346."},{"key":"B20","series-title":"Am J Hematol","first-page":"464","article-title":"Checkpoint inhibitor\u2010based salvage regimens prior to autologous stem cell transplant improve event\u2010free survival in relapsed\/refractory classic Hodgkin lymphoma","volume":"98","author":"Desai SH","year":"2023","unstructured":"Desai SH, Spinner MA, David K,  Checkpoint inhibitor\u2010based salvage regimens prior to autologous stem cell transplant improve event\u2010free survival in relapsed\/refractory classic Hodgkin lymphoma. Am J Hematol 2023;98:464\u2013471."},{"key":"B21","series-title":"Blood","first-page":"182","article-title":"PD-1 blockade before autologous stem cell transplantation improves outcomes in relapsed\/refractory classic Hodgkin lymphoma: results from a multicenter cohort","volume":"142","author":"Desai SH","year":"2023","unstructured":"Desai SH, Merryman RW, Shah H,  PD-1 blockade before autologous stem cell transplantation improves outcomes in relapsed\/refractory classic Hodgkin lymphoma: results from a multicenter cohort. Blood 2023;142(Suppl 1):182."},{"key":"B22","series-title":"Cancer Med","first-page":"7830","article-title":"Effectiveness of chemotherapy after anti\u2010PD\u20101 blockade failure for relapsed and refractory Hodgkin lymphoma","volume":"9","author":"Casadei B","year":"2020","unstructured":"Casadei B, Argnani L, Morigi A,  Effectiveness of chemotherapy after anti\u2010PD\u20101 blockade failure for relapsed and refractory Hodgkin lymphoma. Cancer Med 2020;9:7830\u20137836."},{"key":"B23","series-title":"Oncologist","first-page":"878","article-title":"Checkpoint blockade treatment may sensitize Hodgkin lymphoma to subsequent therapy","volume":"25","author":"Carreau NA","year":"2020","unstructured":"Carreau NA, Pail O, Armand P,  Checkpoint blockade treatment may sensitize Hodgkin lymphoma to subsequent therapy. Oncologist 2020;25:878\u2013885."},{"key":"B24","series-title":"Blood Adv","first-page":"1648","article-title":"Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma","volume":"5","author":"Merryman RW","year":"2021","unstructured":"Merryman RW, Redd RA, Nishihori T,  Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv 2021;5:1648\u20131659."},{"key":"B25","series-title":"Bone Marrow Transplant","first-page":"893","article-title":"Engraftment syndrome following hematopoietic stem cell transplantation","volume":"27","author":"Spitzer T","year":"2001","unstructured":"Spitzer T. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;27:893\u2013898."},{"key":"B26","series-title":"Bone Marrow Transplant","first-page":"393","article-title":"Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria","volume":"31","author":"Maiolino A","year":"2003","unstructured":"Maiolino A, Biasoli I, Lima J,  Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria. Bone Marrow Transplant 2003;31:393\u2013397."},{"key":"B27","series-title":"Bone Marrow Transplant","first-page":"1151","article-title":"Prior anti-PD-1 therapy as a risk factor for life-threatening peri-engraftment respiratory distress syndrome in patients undergoing autologous stem cell transplantation","volume":"56","author":"Bai B","year":"2021","unstructured":"Bai B, Wang XX, Gao Y,  Prior anti-PD-1 therapy as a risk factor for life-threatening peri-engraftment respiratory distress syndrome in patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2021;56:1151\u20131158."},{"key":"B28","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"e726","article-title":"The impact of prior salvage treatment with immune checkpoint inhibitors on Hodgkin lymphoma patients undergoing autologous hematopoietic stem cell transplantation: a single-center experience","volume":"21","author":"Park JJ","year":"2021","unstructured":"Park JJ, Lin J, Huang E, Schaar DG. The impact of prior salvage treatment with immune checkpoint inhibitors on Hodgkin lymphoma patients undergoing autologous hematopoietic stem cell transplantation: a single-center experience. Clin Lymphoma Myeloma Leuk 2021;21:e726\u2013730."},{"key":"B29","series-title":"Blood","first-page":"3603","article-title":"Engraftment syndrome during autologous stem cell transplant in Hodgkin lymphoma patients treated with checkpoint inhibitors: a multi-center retrospective analysis","volume":"142","author":"Taranto E","year":"2023","unstructured":"Taranto E, Hwang WT, Alfaro M,  Engraftment syndrome during autologous stem cell transplant in Hodgkin lymphoma patients treated with checkpoint inhibitors: a multi-center retrospective analysis. Blood 2023;142(Suppl 1):3603."},{"key":"B30","series-title":"JAMA Oncol","first-page":"249","article-title":"Transplant-free approach in relapsed Hodgkin lymphoma in children, adolescents, and young adults","volume":"11","author":"Daw S","year":"2025","unstructured":"Daw S, Cole PD, Hoppe BS,  Transplant-free approach in relapsed Hodgkin lymphoma in children, adolescents, and young adults. JAMA Oncol 2025;11:249\u2013257."},{"key":"B31","series-title":"Haematologica","first-page":"2146","article-title":"Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial","volume":"108","author":"Ding K","year":"2023","unstructured":"Ding K, Liu H, Ma J,  Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial. Haematologica 2023;108:2146\u20132154."},{"key":"B32","series-title":"Blood","first-page":"569","article-title":"Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin","volume":"144","author":"Moskowitz A","year":"2024","unstructured":"Moskowitz A, Shah GL, Ganesan N,  Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin. Blood 2024;144(Suppl 1):569."},{"key":"B33","series-title":"J Clin Oncol","first-page":"1997","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren R","year":"2019","unstructured":"Ramchandren R, Domingo-Dom\u00e8nech E, Rueda A,  Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study. J Clin Oncol 2019;37:1997\u20132007."},{"key":"B34","series-title":"Hematol Oncol","first-page":"146","article-title":"Nivolumab plus doxorubicin, vinblastine and dacarbazine for newly diagnosed advanced\u2010stage classical Hodgkin lymphoma: CheckMate 205 Cohort D 2\u2010year follow\u2010up","volume":"37","author":"Ansell S","year":"2019","unstructured":"Ansell S, Ramchandren R, Domingo\u2010Dom\u00e8nech E,  Nivolumab plus doxorubicin, vinblastine and dacarbazine for newly diagnosed advanced\u2010stage classical Hodgkin lymphoma: CheckMate 205 Cohort D 2\u2010year follow\u2010up. Hematol Oncol 2019;37:146\u2013147."},{"key":"B35","series-title":"Blood","first-page":"1318","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen PB","year":"2021","unstructured":"Allen PB, Savas H, Evens AM,  Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood 2021;137:1318\u20131326."},{"key":"B36","series-title":"Blood Adv","first-page":"2670","article-title":"Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma","volume":"7","author":"Allen PB","year":"2023","unstructured":"Allen PB, Lu X, Chen Q,  Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma. Blood Adv 2023;7:2670\u20132676."},{"key":"B37","series-title":"Blood","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma","volume":"141","author":"Lynch RC","year":"2023","unstructured":"Lynch RC, Ujjani CS, Poh C,  Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma. Blood 2023;141:2576\u20132586."},{"key":"B38","series-title":"Blood","first-page":"2489","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson BD","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L,  Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 2016;128:2489\u20132496."},{"key":"B39","series-title":"Blood","first-page":"290","article-title":"Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma","volume":"145","author":"Lee HJ","year":"2025","unstructured":"Lee HJ, Ramchandren R, Friedman J,  Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood 2025;145:290\u2013299."},{"key":"B40","series-title":"J Clin Oncol","first-page":"1193","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial","volume":"41","author":"Br\u00f6ckelmann PJ","year":"2023","unstructured":"Br\u00f6ckelmann PJ, B\u00fchnen I, Meissner J,  Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial. J Clin Oncol 2023;41:1193\u20131199."},{"key":"B41","series-title":"Blood","first-page":"460","article-title":"Updated analysis of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for nonbulky, early-stage classical Hodgkin lymphoma","volume":"144","author":"Abramson JS","year":"2024","unstructured":"Abramson JS, Straus DJ, Bartlett NL,  Updated analysis of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for nonbulky, early-stage classical Hodgkin lymphoma. Blood 2024;144:460."},{"key":"B42","series-title":"Blood","first-page":"459","article-title":"A randomized phase 2 study incorporating nivolumab and brentuximab vedotin into radiation-free treatment of early stage classic Hodgkin lymphoma","volume":"144","author":"LaCasce AS","year":"2024","unstructured":"LaCasce AS, Jagadeesh D, Lee HJ,  A randomized phase 2 study incorporating nivolumab and brentuximab vedotin into radiation-free treatment of early stage classic Hodgkin lymphoma. Blood 2024;144(Suppl 1):459."},{"key":"B43","series-title":"J Clin Oncol","first-page":"985","article-title":"Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma","volume":"43","author":"Torka P","year":"2025","unstructured":"Torka P, Feldman T, Savage KJ,  Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma. J Clin Oncol 2025;43:985\u2013993."},{"key":"B44","series-title":"J Clin Oncol","article-title":"Nivolumab-AVD versus brentuximab vedotin\u2013AVD in older patients with advanced-stage classic Hodgkin lymphoma enrolled on S1826","author":"Rutherford SC","year":"2025","unstructured":"Rutherford SC, Li H, Herrera AF,  Nivolumab-AVD versus brentuximab vedotin\u2013AVD in older patients with advanced-stage classic Hodgkin lymphoma enrolled on S1826. J Clin Oncol 2025;43:2968\u20132973."},{"key":"B45","series-title":"J Clin Oncol","first-page":"3015","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens AM","year":"2018","unstructured":"Evens AM, Advani RH, Helenowski IB,  Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol 2018;36:3015\u20133022."},{"key":"B46","series-title":"Blood Adv","first-page":"3750","article-title":"Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results","volume":"9","author":"Cheson BD","year":"2025","unstructured":"Cheson BD, Bartlett NL, Knopf B,  Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results. Blood Adv 2025;9:3750\u20133753."},{"key":"B47","series-title":"Blood","first-page":"786","article-title":"Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy","volume":"143","author":"Friedberg JW","year":"2024","unstructured":"Friedberg JW, Bordoni R, Patel-Donnelly D,  Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood 2024;143:786\u2013795."},{"key":"B48","series-title":"Expert Opin Emerg Drugs","first-page":"263","article-title":"Emerging immunotherapies in the Hodgkin lymphoma armamentarium","volume":"29","author":"Spinner MA","year":"2024","unstructured":"Spinner MA, Advani RH. Emerging immunotherapies in the Hodgkin lymphoma armamentarium. Expert Opin Emerg Drugs 2024;29:263\u2013275."},{"key":"B49","series-title":"Blood","first-page":"1359","article-title":"Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade","volume":"142","author":"Mei M","year":"2023","unstructured":"Mei M, Chen L, Godfrey J,  Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade. Blood 2023;142:1359\u20131370."},{"key":"B50","series-title":"J Clin Oncol","first-page":"1479","article-title":"Addition of low-dose decitabine to anti\u2013PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma","volume":"37","author":"Nie J","year":"2019","unstructured":"Nie J, Wang C, Liu Y,  Addition of low-dose decitabine to anti\u2013PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma. J Clin Oncol 2019;37:1479\u20131489."},{"key":"B51","series-title":"Clin Cancer Res","first-page":"2782","article-title":"Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy","volume":"27","author":"Wang C","year":"2021","unstructured":"Wang C, Liu Y, Dong L,  Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy. Clin Cancer Res 2021;27:2782\u20132791."},{"key":"B52","series-title":"Blood","first-page":"1697","article-title":"The combination of nivolumab and CC-486 is active in Hodgkin lymphoma refractory to PD-1 blockade","volume":"142","author":"Mei MG","year":"2023","unstructured":"Mei MG, Chen L, Puverel S,  The combination of nivolumab and CC-486 is active in Hodgkin lymphoma refractory to PD-1 blockade. Blood 2023;142(Suppl 1):1697."},{"key":"B53","series-title":"Hemasphere","first-page":"e401","article-title":"A study of safety and efficacy of nivolumab and bendamustine (NB) in patients with relapsed\/refractory Hodgkin lymphoma after nivolumab monotherapy failure","volume":"4","author":"Lepik KV","year":"2020","unstructured":"Lepik KV, Mikhailova NB, Kondakova EV,  A study of safety and efficacy of nivolumab and bendamustine (NB) in patients with relapsed\/refractory Hodgkin lymphoma after nivolumab monotherapy failure. Hemasphere 2020;4:e401."},{"key":"B54","series-title":"Br J Haematol","first-page":"e17","article-title":"Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma","volume":"204","author":"Stuver R","year":"2024","unstructured":"Stuver R, Noy A, Vardhana SA,  Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma. Br J Haematol 2024;204:e17\u201320."},{"key":"B55","series-title":"Blood Adv","first-page":"1242","article-title":"Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma","volume":"4","author":"De Philippis C","year":"2020","unstructured":"De Philippis C, Legrand-Izadifar F, Bramanti S,  Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. Blood Adv 2020;4:1242\u20131249."},{"key":"B56","series-title":"Blood Adv","first-page":"1202","article-title":"Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma","volume":"9","author":"Tabbara N","year":"2025","unstructured":"Tabbara N, Zahurak M, Sterling CH,  Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma. Blood Adv 2025;9:1202\u20131209."},{"key":"B57","series-title":"Blood","first-page":"1011","article-title":"Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis","volume":"146","author":"Perales MA","year":"2025","unstructured":"Perales MA, Awan FT, Boumendil A,  Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis. Blood 2025;146:1011\u20131029."},{"key":"B58","series-title":"Blood","first-page":"9","article-title":"Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil","volume":"132","author":"Herbaux C","year":"2018","unstructured":"Herbaux C, Merryman R, Devine S,  Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood 2018;132:9\u201316."},{"key":"B59","series-title":"Leukemia","first-page":"2672","article-title":"Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma","volume":"35","author":"Merryman RW","year":"2021","unstructured":"Merryman RW, Castagna L, Giordano L,  Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia 2021;35:2672\u20132683."},{"key":"B60","series-title":"J Clin Oncol","first-page":"942","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer MGM","year":"2018","unstructured":"Roemer MGM, Redd RA, Cader FZ,  Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J Clin Oncol 2018;36:942\u2013950."},{"key":"B61","series-title":"Nat Med","first-page":"1468","article-title":"A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma","volume":"26","author":"Cader FZ","year":"2020","unstructured":"Cader FZ, Hu X, Goh WL,  A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat Med 2020;26:1468\u20131479."},{"issue":"14","key":"B62","series-title":"Hematol Oncol","article-title":"Impact of EBV status and histology on outcomes with nivolumab\u2010AVD versus BV\u2010AVD in patients enrolled on SWOG S1826","volume":"43","author":"Ahmed S","year":"2025","unstructured":"Ahmed S, Li H, Herrera AF,  Impact of EBV status and histology on outcomes with nivolumab\u2010AVD versus BV\u2010AVD in patients enrolled on SWOG S1826. Hematol Oncol 2025;43:14."},{"key":"B63","series-title":"Blood","first-page":"565","article-title":"Ultrasensitive circulating tumor DNA MRD status predicts treatment failure and complements PET\/CT throughout treatment for early and advanced stage classic Hodgkin lymphoma","volume":"144","author":"Boegeholz J","year":"2024","unstructured":"Boegeholz J, Rossi C, Goldstein JS,  Ultrasensitive circulating tumor DNA MRD status predicts treatment failure and complements PET\/CT throughout treatment for early and advanced stage classic Hodgkin lymphoma. Blood 2024;144(Suppl 1):565."},{"key":"B64","series-title":"Blood","first-page":"1207","article-title":"A comprehensive genetic study of classical Hodgkin lymphoma using circulating tumor DNA","volume":"146","author":"Pirosa MC","year":"2025","unstructured":"Pirosa MC, Bruscaggin A, Terzi di Bergamo L,  A comprehensive genetic study of classical Hodgkin lymphoma using circulating tumor DNA. Blood 2025;146:1207\u20131224."},{"key":"B1","series-title":"N Engl J Med","first-page":"1379","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera AF","year":"2024","unstructured":"Herrera AF, LeBlanc M, Castellino SM,  Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma. N Engl J Med 2024;391:1379\u20131389."},{"key":"B2","series-title":"Blood","first-page":"2727","article-title":"Improved outcomes for relapsed\/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents","volume":"141","author":"Spinner MA","year":"2023","unstructured":"Spinner MA, Sica RA, Tamaresis JS,  Improved outcomes for relapsed\/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood 2023;141:2727\u20132737."},{"key":"B3","series-title":"N Engl J Med","first-page":"311","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell SM","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I,  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 2015;372:311\u2013319."},{"key":"B4","series-title":"J Clin Oncol","first-page":"2125","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen R","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA,  Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35:2125\u20132132."},{"key":"B5","series-title":"J Clin Oncol","first-page":"2690","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer MGM","year":"2016","unstructured":"Roemer MGM, Advani RH, Ligon AH,  PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 2016;34:2690\u20132697."},{"key":"B6","series-title":"Blood","first-page":"2420","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey CD","year":"2017","unstructured":"Carey CD, Gusenleitner D, Lipschitz M,  Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood 2017;130:2420\u20132430."},{"key":"B7","series-title":"Lancet Oncol","first-page":"1283","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes A","year":"2016","unstructured":"Younes A, Santoro A, Shipp M,  Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17:1283\u20131294."},{"key":"B8","series-title":"Blood Adv","first-page":"6266","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study","volume":"7","author":"Ansell SM","year":"2023","unstructured":"Ansell SM, Br\u00f6ckelmann PJ, von Keudell G,  Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv 2023;7:6266\u20136274."},{"key":"B9","series-title":"Blood","first-page":"878","article-title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"Armand P","year":"2023","unstructured":"Armand P, Zinzani PL, Lee HJ,  Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma. Blood 2023;142:878\u2013886."},{"key":"B10","series-title":"Lancet Oncol","first-page":"512","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla J","year":"2021","unstructured":"Kuruvilla J, Ramchandren R, Santoro A,  Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021;22:512\u2013524."},{"key":"B11","series-title":"Blood Adv","first-page":"590","article-title":"Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed\/refractory classical Hodgkin lymphoma","volume":"6","author":"Zinzani PL","year":"2022","unstructured":"Zinzani PL, Ramchandren R, Santoro A,  Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed\/refractory classical Hodgkin lymphoma. Blood Adv 2022;6:590\u2013599."},{"key":"B12","article-title":"NCCN Guidelines\u00ae Insights: Hodgkin Lymphoma, Version 1.2026","author":"Advani RH","unstructured":"Advani RH, Kelsey CR, Armand P,  NCCN Guidelines\u00ae Insights: Hodgkin Lymphoma, Version 1.2026. Accessed December 16, 2025. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf"},{"key":"B13","series-title":"Blood","first-page":"4934","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz AJ","year":"2010","unstructured":"Moskowitz AJ, Yahalom J, Kewalramani T,  Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010;116:4934\u20134937."},{"key":"B14","series-title":"Cancers (Basel)","first-page":"4509.","article-title":"Optimizing treatment for relapsed\/refractory classic Hodgkin lymphoma in the era of immunotherapy","volume":"15","author":"Randall MP","year":"2023","unstructured":"Randall MP, Spinner MA. Optimizing treatment for relapsed\/refractory classic Hodgkin lymphoma in the era of immunotherapy. Cancers (Basel) 2023;15:4509."},{"key":"B15","series-title":"Blood","first-page":"427","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani RH","year":"2021","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL,  Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood 2021;138:427\u2013438."},{"key":"B16","series-title":"Blood","first-page":"3605","article-title":"Response-adapted anti-PD-1\u2013based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei MG","year":"2022","unstructured":"Mei MG, Lee HJ, Palmer JM,  Response-adapted anti-PD-1\u2013based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood 2022;139:3605\u20133616."},{"key":"B17","series-title":"JAMA Oncol","first-page":"683","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma","volume":"9","author":"Bryan LJ","year":"2023","unstructured":"Bryan LJ, Casulo C, Allen PB,  Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma. JAMA Oncol 2023;9:683\u2013691."},{"key":"B18","series-title":"J Clin Oncol","first-page":"3109","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz AJ","year":"2021","unstructured":"Moskowitz AJ, Shah G, Sch\u00f6der H,  Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol 2021;39:3109\u20133117."},{"key":"B19","series-title":"Hemasphere","first-page":"45","article-title":"T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma","volume":"6","author":"Moskowitz AJ","year":"2022","unstructured":"Moskowitz AJ, Shah G, Sch\u00f6der H,  T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma. Hemasphere 2022;6:45\u201346."},{"key":"B20","series-title":"Am J Hematol","first-page":"464","article-title":"Checkpoint inhibitor\u2010based salvage regimens prior to autologous stem cell transplant improve event\u2010free survival in relapsed\/refractory classic Hodgkin lymphoma","volume":"98","author":"Desai SH","year":"2023","unstructured":"Desai SH, Spinner MA, David K,  Checkpoint inhibitor\u2010based salvage regimens prior to autologous stem cell transplant improve event\u2010free survival in relapsed\/refractory classic Hodgkin lymphoma. Am J Hematol 2023;98:464\u2013471."},{"key":"B21","series-title":"Blood","first-page":"182","article-title":"PD-1 blockade before autologous stem cell transplantation improves outcomes in relapsed\/refractory classic Hodgkin lymphoma: results from a multicenter cohort","volume":"142","author":"Desai SH","year":"2023","unstructured":"Desai SH, Merryman RW, Shah H,  PD-1 blockade before autologous stem cell transplantation improves outcomes in relapsed\/refractory classic Hodgkin lymphoma: results from a multicenter cohort. Blood 2023;142(Suppl 1):182."},{"key":"B22","series-title":"Cancer Med","first-page":"7830","article-title":"Effectiveness of chemotherapy after anti\u2010PD\u20101 blockade failure for relapsed and refractory Hodgkin lymphoma","volume":"9","author":"Casadei B","year":"2020","unstructured":"Casadei B, Argnani L, Morigi A,  Effectiveness of chemotherapy after anti\u2010PD\u20101 blockade failure for relapsed and refractory Hodgkin lymphoma. Cancer Med 2020;9:7830\u20137836."},{"key":"B23","series-title":"Oncologist","first-page":"878","article-title":"Checkpoint blockade treatment may sensitize Hodgkin lymphoma to subsequent therapy","volume":"25","author":"Carreau NA","year":"2020","unstructured":"Carreau NA, Pail O, Armand P,  Checkpoint blockade treatment may sensitize Hodgkin lymphoma to subsequent therapy. Oncologist 2020;25:878\u2013885."},{"key":"B24","series-title":"Blood Adv","first-page":"1648","article-title":"Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma","volume":"5","author":"Merryman RW","year":"2021","unstructured":"Merryman RW, Redd RA, Nishihori T,  Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv 2021;5:1648\u20131659."},{"key":"B25","series-title":"Bone Marrow Transplant","first-page":"893","article-title":"Engraftment syndrome following hematopoietic stem cell transplantation","volume":"27","author":"Spitzer T","year":"2001","unstructured":"Spitzer T. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;27:893\u2013898."},{"key":"B26","series-title":"Bone Marrow Transplant","first-page":"393","article-title":"Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria","volume":"31","author":"Maiolino A","year":"2003","unstructured":"Maiolino A, Biasoli I, Lima J,  Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria. Bone Marrow Transplant 2003;31:393\u2013397."},{"key":"B27","series-title":"Bone Marrow Transplant","first-page":"1151","article-title":"Prior anti-PD-1 therapy as a risk factor for life-threatening peri-engraftment respiratory distress syndrome in patients undergoing autologous stem cell transplantation","volume":"56","author":"Bai B","year":"2021","unstructured":"Bai B, Wang XX, Gao Y,  Prior anti-PD-1 therapy as a risk factor for life-threatening peri-engraftment respiratory distress syndrome in patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2021;56:1151\u20131158."},{"key":"B28","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"e726","article-title":"The impact of prior salvage treatment with immune checkpoint inhibitors on Hodgkin lymphoma patients undergoing autologous hematopoietic stem cell transplantation: a single-center experience","volume":"21","author":"Park JJ","year":"2021","unstructured":"Park JJ, Lin J, Huang E, Schaar DG. The impact of prior salvage treatment with immune checkpoint inhibitors on Hodgkin lymphoma patients undergoing autologous hematopoietic stem cell transplantation: a single-center experience. Clin Lymphoma Myeloma Leuk 2021;21:e726\u2013730."},{"key":"B29","series-title":"Blood","first-page":"3603","article-title":"Engraftment syndrome during autologous stem cell transplant in Hodgkin lymphoma patients treated with checkpoint inhibitors: a multi-center retrospective analysis","volume":"142","author":"Taranto E","year":"2023","unstructured":"Taranto E, Hwang WT, Alfaro M,  Engraftment syndrome during autologous stem cell transplant in Hodgkin lymphoma patients treated with checkpoint inhibitors: a multi-center retrospective analysis. Blood 2023;142(Suppl 1):3603."},{"key":"B30","series-title":"JAMA Oncol","first-page":"249","article-title":"Transplant-free approach in relapsed Hodgkin lymphoma in children, adolescents, and young adults","volume":"11","author":"Daw S","year":"2025","unstructured":"Daw S, Cole PD, Hoppe BS,  Transplant-free approach in relapsed Hodgkin lymphoma in children, adolescents, and young adults. JAMA Oncol 2025;11:249\u2013257."},{"key":"B31","series-title":"Haematologica","first-page":"2146","article-title":"Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial","volume":"108","author":"Ding K","year":"2023","unstructured":"Ding K, Liu H, Ma J,  Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial. Haematologica 2023;108:2146\u20132154."},{"key":"B32","series-title":"Blood","first-page":"569","article-title":"Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin","volume":"144","author":"Moskowitz A","year":"2024","unstructured":"Moskowitz A, Shah GL, Ganesan N,  Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin. Blood 2024;144(Suppl 1):569."},{"key":"B33","series-title":"J Clin Oncol","first-page":"1997","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren R","year":"2019","unstructured":"Ramchandren R, Domingo-Dom\u00e8nech E, Rueda A,  Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study. J Clin Oncol 2019;37:1997\u20132007."},{"key":"B34","series-title":"Hematol Oncol","first-page":"146","article-title":"Nivolumab plus doxorubicin, vinblastine and dacarbazine for newly diagnosed advanced\u2010stage classical Hodgkin lymphoma: CheckMate 205 Cohort D 2\u2010year follow\u2010up","volume":"37","author":"Ansell S","year":"2019","unstructured":"Ansell S, Ramchandren R, Domingo\u2010Dom\u00e8nech E,  Nivolumab plus doxorubicin, vinblastine and dacarbazine for newly diagnosed advanced\u2010stage classical Hodgkin lymphoma: CheckMate 205 Cohort D 2\u2010year follow\u2010up. Hematol Oncol 2019;37:146\u2013147."},{"key":"B35","series-title":"Blood","first-page":"1318","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen PB","year":"2021","unstructured":"Allen PB, Savas H, Evens AM,  Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood 2021;137:1318\u20131326."},{"key":"B36","series-title":"Blood Adv","first-page":"2670","article-title":"Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma","volume":"7","author":"Allen PB","year":"2023","unstructured":"Allen PB, Lu X, Chen Q,  Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma. Blood Adv 2023;7:2670\u20132676."},{"key":"B37","series-title":"Blood","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma","volume":"141","author":"Lynch RC","year":"2023","unstructured":"Lynch RC, Ujjani CS, Poh C,  Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma. Blood 2023;141:2576\u20132586."},{"key":"B38","series-title":"Blood","first-page":"2489","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson BD","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L,  Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 2016;128:2489\u20132496."},{"key":"B39","series-title":"Blood","first-page":"290","article-title":"Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma","volume":"145","author":"Lee HJ","year":"2025","unstructured":"Lee HJ, Ramchandren R, Friedman J,  Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood 2025;145:290\u2013299."},{"key":"B40","series-title":"J Clin Oncol","first-page":"1193","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial","volume":"41","author":"Br\u00f6ckelmann PJ","year":"2023","unstructured":"Br\u00f6ckelmann PJ, B\u00fchnen I, Meissner J,  Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial. J Clin Oncol 2023;41:1193\u20131199."},{"key":"B41","series-title":"Blood","first-page":"460","article-title":"Updated analysis of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for nonbulky, early-stage classical Hodgkin lymphoma","volume":"144","author":"Abramson JS","year":"2024","unstructured":"Abramson JS, Straus DJ, Bartlett NL,  Updated analysis of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for nonbulky, early-stage classical Hodgkin lymphoma. Blood 2024;144:460."},{"key":"B42","series-title":"Blood","first-page":"459","article-title":"A randomized phase 2 study incorporating nivolumab and brentuximab vedotin into radiation-free treatment of early stage classic Hodgkin lymphoma","volume":"144","author":"LaCasce AS","year":"2024","unstructured":"LaCasce AS, Jagadeesh D, Lee HJ,  A randomized phase 2 study incorporating nivolumab and brentuximab vedotin into radiation-free treatment of early stage classic Hodgkin lymphoma. Blood 2024;144(Suppl 1):459."},{"key":"B43","series-title":"J Clin Oncol","first-page":"985","article-title":"Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma","volume":"43","author":"Torka P","year":"2025","unstructured":"Torka P, Feldman T, Savage KJ,  Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma. J Clin Oncol 2025;43:985\u2013993."},{"key":"B44","series-title":"J Clin Oncol","article-title":"Nivolumab-AVD versus brentuximab vedotin\u2013AVD in older patients with advanced-stage classic Hodgkin lymphoma enrolled on S1826","author":"Rutherford SC","year":"2025","unstructured":"Rutherford SC, Li H, Herrera AF,  Nivolumab-AVD versus brentuximab vedotin\u2013AVD in older patients with advanced-stage classic Hodgkin lymphoma enrolled on S1826. J Clin Oncol 2025;43:2968\u20132973."},{"key":"B45","series-title":"J Clin Oncol","first-page":"3015","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens AM","year":"2018","unstructured":"Evens AM, Advani RH, Helenowski IB,  Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol 2018;36:3015\u20133022."},{"key":"B46","series-title":"Blood Adv","first-page":"3750","article-title":"Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results","volume":"9","author":"Cheson BD","year":"2025","unstructured":"Cheson BD, Bartlett NL, Knopf B,  Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results. Blood Adv 2025;9:3750\u20133753."},{"key":"B47","series-title":"Blood","first-page":"786","article-title":"Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy","volume":"143","author":"Friedberg JW","year":"2024","unstructured":"Friedberg JW, Bordoni R, Patel-Donnelly D,  Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood 2024;143:786\u2013795."},{"key":"B48","series-title":"Expert Opin Emerg Drugs","first-page":"263","article-title":"Emerging immunotherapies in the Hodgkin lymphoma armamentarium","volume":"29","author":"Spinner MA","year":"2024","unstructured":"Spinner MA, Advani RH. Emerging immunotherapies in the Hodgkin lymphoma armamentarium. Expert Opin Emerg Drugs 2024;29:263\u2013275."},{"key":"B49","series-title":"Blood","first-page":"1359","article-title":"Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade","volume":"142","author":"Mei M","year":"2023","unstructured":"Mei M, Chen L, Godfrey J,  Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade. Blood 2023;142:1359\u20131370."},{"key":"B50","series-title":"J Clin Oncol","first-page":"1479","article-title":"Addition of low-dose decitabine to anti\u2013PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma","volume":"37","author":"Nie J","year":"2019","unstructured":"Nie J, Wang C, Liu Y,  Addition of low-dose decitabine to anti\u2013PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma. J Clin Oncol 2019;37:1479\u20131489."},{"key":"B51","series-title":"Clin Cancer Res","first-page":"2782","article-title":"Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy","volume":"27","author":"Wang C","year":"2021","unstructured":"Wang C, Liu Y, Dong L,  Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy. Clin Cancer Res 2021;27:2782\u20132791."},{"key":"B52","series-title":"Blood","first-page":"1697","article-title":"The combination of nivolumab and CC-486 is active in Hodgkin lymphoma refractory to PD-1 blockade","volume":"142","author":"Mei MG","year":"2023","unstructured":"Mei MG, Chen L, Puverel S,  The combination of nivolumab and CC-486 is active in Hodgkin lymphoma refractory to PD-1 blockade. Blood 2023;142(Suppl 1):1697."},{"key":"B53","series-title":"Hemasphere","first-page":"e401","article-title":"A study of safety and efficacy of nivolumab and bendamustine (NB) in patients with relapsed\/refractory Hodgkin lymphoma after nivolumab monotherapy failure","volume":"4","author":"Lepik KV","year":"2020","unstructured":"Lepik KV, Mikhailova NB, Kondakova EV,  A study of safety and efficacy of nivolumab and bendamustine (NB) in patients with relapsed\/refractory Hodgkin lymphoma after nivolumab monotherapy failure. Hemasphere 2020;4:e401."},{"key":"B54","series-title":"Br J Haematol","first-page":"e17","article-title":"Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma","volume":"204","author":"Stuver R","year":"2024","unstructured":"Stuver R, Noy A, Vardhana SA,  Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma. Br J Haematol 2024;204:e17\u201320."},{"key":"B55","series-title":"Blood Adv","first-page":"1242","article-title":"Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma","volume":"4","author":"De Philippis C","year":"2020","unstructured":"De Philippis C, Legrand-Izadifar F, Bramanti S,  Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. Blood Adv 2020;4:1242\u20131249."},{"key":"B56","series-title":"Blood Adv","first-page":"1202","article-title":"Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma","volume":"9","author":"Tabbara N","year":"2025","unstructured":"Tabbara N, Zahurak M, Sterling CH,  Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma. Blood Adv 2025;9:1202\u20131209."},{"key":"B57","series-title":"Blood","first-page":"1011","article-title":"Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis","volume":"146","author":"Perales MA","year":"2025","unstructured":"Perales MA, Awan FT, Boumendil A,  Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis. Blood 2025;146:1011\u20131029."},{"key":"B58","series-title":"Blood","first-page":"9","article-title":"Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil","volume":"132","author":"Herbaux C","year":"2018","unstructured":"Herbaux C, Merryman R, Devine S,  Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood 2018;132:9\u201316."},{"key":"B59","series-title":"Leukemia","first-page":"2672","article-title":"Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma","volume":"35","author":"Merryman RW","year":"2021","unstructured":"Merryman RW, Castagna L, Giordano L,  Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia 2021;35:2672\u20132683."},{"key":"B60","series-title":"J Clin Oncol","first-page":"942","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer MGM","year":"2018","unstructured":"Roemer MGM, Redd RA, Cader FZ,  Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J Clin Oncol 2018;36:942\u2013950."},{"key":"B61","series-title":"Nat Med","first-page":"1468","article-title":"A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma","volume":"26","author":"Cader FZ","year":"2020","unstructured":"Cader FZ, Hu X, Goh WL,  A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat Med 2020;26:1468\u20131479."},{"issue":"14","key":"B62","series-title":"Hematol Oncol","article-title":"Impact of EBV status and histology on outcomes with nivolumab\u2010AVD versus BV\u2010AVD in patients enrolled on SWOG S1826","volume":"43","author":"Ahmed S","year":"2025","unstructured":"Ahmed S, Li H, Herrera AF,  Impact of EBV status and histology on outcomes with nivolumab\u2010AVD versus BV\u2010AVD in patients enrolled on SWOG S1826. Hematol Oncol 2025;43:14."},{"key":"B63","series-title":"Blood","first-page":"565","article-title":"Ultrasensitive circulating tumor DNA MRD status predicts treatment failure and complements PET\/CT throughout treatment for early and advanced stage classic Hodgkin lymphoma","volume":"144","author":"Boegeholz J","year":"2024","unstructured":"Boegeholz J, Rossi C, Goldstein JS,  Ultrasensitive circulating tumor DNA MRD status predicts treatment failure and complements PET\/CT throughout treatment for early and advanced stage classic Hodgkin lymphoma. Blood 2024;144(Suppl 1):565."},{"key":"B64","series-title":"Blood","first-page":"1207","article-title":"A comprehensive genetic study of classical Hodgkin lymphoma using circulating tumor DNA","volume":"146","author":"Pirosa MC","year":"2025","unstructured":"Pirosa MC, Bruscaggin A, Terzi di Bergamo L,  A comprehensive genetic study of classical Hodgkin lymphoma using circulating tumor DNA. Blood 2025;146:1207\u20131224."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/2\/article-e257125.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/2\/article-e257125.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/2\/article-e257125.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T13:46:29Z","timestamp":1770644789000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/2\/article-e257125.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":128,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7125","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}